Antisense oligonucleotide therapeutics for human leukemia

Critical Reviews in Oncogenesis

Volumn 8, Issue 1, 1997, Pages 93-109

  Gewirtz, Alan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisense; bcr abl; c kit; c myb; CML; Hematopoiesis; Leukemia; Oligodeoxynucleotide; Ribozyme; vav

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; ONCOPROTEIN; PROTEIN P53;

ACUTE LEUKEMIA; CHRONIC MYELOID LEUKEMIA; GENE DISRUPTION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; LEUKEMIA; LYMPHOMA; NONHUMAN; ONCOGENE C MYB; REVIEW;

EID: 0031431502     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v8.i1.50     Document Type: Review

References (131)

1. Paterson, B. M., B. E. Roberts, and E. L. Kuff: Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc. Natl. Acad. Sci. U.S.A., 74(10):4370-4 (1977).
2. Stephenson, M. L. and P. C. Zamecnik: Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. U.S.A., 75(1):285-8(1978).
3. Mizuno, T., M. Y. Chou, and M. Inouye: A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA). Proc. Natl. Acad. Sci. U.S.A., 81(7):1966-70 (1984).
4. Simons, R. W. and N. Kleckner: Biological regulation by antisense RNA in prokaryotes. Ann. Rev. Genet., 22:567-600 (1988).
5. Izant, J. G. and H. Weintraub: Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science, 229(4711):345-52 (1985).
6. Izant, J. G., and H. Weintraub: Inhibition of thymidine kinase gene expression by anti-sense RNA: a molecular approach to genetic analysis. Cell, 36(4):1007-15 (1984).
7. Melton, D. W.: Gene targeting in the mouse. Bioessays, 16(9):633-8 (1994).
8. Helene, C.: Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur. J. Cancer, 27(11):1466-71 (1991).
9. Sharma, H. W., J. R. Perez, K. Higgins-Sochaski, R. Hsiao, and R. Narayanan: Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res., 16(1):61-9 (1996).
10. Morishita, R., G. H. Gibbons, M. Horiuchi, K. E. Ellison, M. Nakama, L. Zhang, Y. Kaneda, T. Ogihara, and V. J. Dzau: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. U.S.A., 92(13):5855-9 (1995).
11. Gunther, E. J., T. M. Yeasky, F. P. Gasparro, and P. M. Glazer: Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by offoadducts as well as cross-links. Cancer Res., 55(6):1283-8 (1995).
12. Gunther, E. J., P. A. Havre, F. P. Gasparro, and P. M. Glazer: Triplex-mediated, in vitro targeting of psoralen photoadducts within the genome of a transgenic mouse. Photochem. Photobiol., 63(2):207-12 (1996).
13. Raha, M., G. Wang, M. M. Seidman, and P. M. Glazer: Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant. Proc. Natl. Acad. Sci. U.S.A., 93(7):2941-6 (1996).
14. Kim, U., Y. Wang, T. Sanford, Y. Zeng, and K. Nishikura: Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc. Natl. Acad. Sci. U.S.A., 91(24): 11457-61 (1994).
15. Eder, P. S. and J. A. Walder: Ribonuclease H from K562 human erythroleukemia cells. Purification, characterization, and substrate specificity. J. Biol. Chem., 266(10):6472-9 (1991).
16. Eder, P. S., R. Y. Walder, and J. A. Walder: 1993Substrate specificity of human RNase HI and its role in excision repair of ribose residues misincorporated in DNA. Biochimie, 75(1-2):123-6.
17. Stein, C. A.: Does antisense exist? Nat. Med., 1(11):1119-21 (1995).
18. Nellen, W. and C. Lichtenstein: What makes an mRNA anti-senseitive? Trends Biochem. Sci., 18(11):419-23 (1993).
19. Ratajczak, M. Z., S. M. Luger, K. DeRiel, J. Abrahm, B. Calabretta, and A. M. Gewirtz: Role of the KIT protooncogene in normal and malignant human hematopoiesis. Proc. Natl. Acad. Sci. U.S.A., 89(5):1710-4, (1992).
20. Metcalf, D.: Blood. Thrombopoietin - at last [news; comment]. Nature, 369(6481):519-20 (1994).
21. Methia, N., F. Louache, W. Vainchenker, and F. Wendling: Oligodeoxynucleotides antisense to the protooncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood, 82(5):1395-401 (1993).
22. Gewirtz, A. M. and B. Calabretta: A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science, 242(4883):1303-6 (1988).
23. Gewirtz, A. M., C. A. Stein, and P. M. Glazer: Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proc. Natl. Acad. Sci. U.S.A., 93(8):3161-3 (1996).
24. Ratajczak, M. Z., S. M. Luger, and A. M. Gewirtz: The c-kit protooncogene in normal and malignant human hematopoiesis. Int. J. Cell Cloning, 10(4):205-14 (1992).
25. Gewirtz, A. M.: Potential therapeutic applications of antisense Oligodeoxynucleotides in the treatment of chronic myelogenous leukemia. Leuk. Lymphoma, 11(Suppl.)1:131-7 (1993).
26. Gewirtz, A. M.: Treatment of chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotides. Bone Marrow Transplant, 14(Suppl. 3):S57-61 (1994).
27. Ratajczak, M. Z., N. Hijiya, L. Catani, K. DeRiel, S. M. Luger, P. McGlave, and A. M. Gewirtz: Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleo-tides. Blood, 79(8):1956-61 (1992).
28. Calabretta, B., R. B. Sims, M. Valtieri, D. Caracciolo, C. Szczylik, D. Venturelli, M. Ratajczak, M. Beran, and A. M. Gewirtz: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. U.S.A., 88(6):2351-5, (1991).
29. Bacon, T. A. and E. Wickstrom: Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media. Oncogene Res., 6(1):21-32 (1991).
30. Barut, B., D. Chauhan, H. Uchiyama, and K. C. Anderson: Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro. J. Clin. Invest., 92(5):2346-52 (1993).
31. Bertram, J., K. Palfner, M. Killian, W. Brysch, K. H. Schlingensiepen, W. Hiddemann, and M. Kneba: Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs, 6(1):124-34 (1995).
32. Bishop, M. R., P. I. Warkentin, J. D. Jackson, E. Bayever, P. L. Iversen, V. I. Whalen, J. Lastovica, K. Haines, and A. Kessinger: Antisense oligonucleotide OL (1) p53 for in vitro purging of autologous bone marrow in acute myelogenous leukemia. Prog. Clin. Biol. Res., 389:183-7 (1994).
33. Brennscheidt, U., D. Riedel, W. Kolch, R. Bonifer, M. A. Brach, A. Ahlers, R. H. Mertelsmann, and F. Herrmann: Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9. Cell Growth Differ., 5(4):367-72 (1994).
34. Campos, L., O. Sabido, J. P. Rouault, and D. Guyotat: Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood, 84(2):595-600 (1994).
35. Cantor, G. H. and G. H. Palmer: Antisense oligonucleotide inhibition of bovine leukemia virus tax expression in a cell-free system. Antisense Res. Dev., 2(2):147-52 (1992).
36. Ferrari, S., A. Donelli, R. Manfredini, M. Sarti, R. Roncaglia, E. Tagliafico, E. Rossi, G. Torelli, and U. Torelli: Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells. Cell Growth Differ., 1(11):543-8 (1990).
37. Keith, F. J., D. A. Bradbury, Y. M. Zhu, and N. H. Russell: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia, 9(1):131-8 (1995).
38. Kitajima, I., T. Shinohara, J. Bilakovics, D. A. Brown, X. Xu, and M. Nerenberg: Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B [published erratum appears in Science 1993 Mar 12;259(5101):1523]. Science, 258(5089):1792-5 (1992).
39. Lill, M. C., J. F. Fuller, R. Herzig, G. M. Crooks, and J. C. Gasson: The role of the homeobox gene, HOX B7, in human myelomonocytic differentiation. Blood, 85(3):692-7 (1995).
40. Manfredini, R., A. Grande, E. Tagliafico, D. Barbieri, P. Zucchini, G. Citro, G. Zupi, C. Franceschi, U. Torelli, and S. Ferrari: Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation. J. Exp. Med., 178(2):381-9 (1993).
41. Sakakura, C., Y. Yamaguchi-Iwai, M. Satake, S. C. Bae, A. Takahashi, E. Ogawa, A. Hagiwara, T. Takahashi, A. Murakami, K. Makino, et al.: Growth inhibition and induction of differentiation of t(8;21) acute myeloid leukemia cells by the DNA-binding domain of PEBP2 and the AMLl/MTG8(ETO)-specific antisense oligonucleotide. Proc. Natl. Acad. Sci. U.S.A., 91(24):11723-7 (1994).
42. Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Ratajczak, C. Szczylik, G. Zon, R. B. Arlinghaus, A. Gewirtz, B. Perussia, and B. Calabretta: p120 GAP requirement in normal and malignant human hematopoiesis. J. Exp. Med., 178(6):1923-33 (1993).
43. Sokoloski, J. A., A. C. Sartorelli, C. A. Rosen, and R. Narayanan: Antisense oligonucleotides to the p65 subunit of NF-kappa B block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood, 82(2):625-32 (1993).
44. Takeshita, K., J. A. Bollekens, N. Hijiya, M. Ratajczak, F. H. Ruddle, and A. M. Gewirtz: A homeobox gene of the Antennapedia class is required for human adult erythropoiesis. Proc. Natl. Acad. Sci. U.S.A., 90(8):3535-8 (1993).
45. Tortora, G., H. Yokozaki, S. Pepe, T. Clair, and Y. S. Cho-Chung: Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U.S.A., 88(5):2011-5 (1991).
46. Arsura, M., M. Introna, F. Passerini, A. Mantovani, and J. Golay: B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. Blood, 79(10):2708-16 (1992).
47. Waki, M., A. Kitanaka, H. Kamano, T. Tanaka, Y. Kubota, H. Ohnishi, J. Takahara, and S. Irino: Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression. Biochem. Biophys. Res. Commun., 201(2):1001-7 (1994).
48. Skorski, T., M. Nieborowska-Skorska, C. Szczylik, P. Kanakaraj, D. Perrotti, G. Zon, A. Gewirtz, B. Perussia, and B. Calabretta: C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res., 55(11):2275-8 (1995).
49. Giles, R. V., C. J. Ruddell, D. G. Spiller, J. A. Green, and D. M. Tidd: Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res., 23(6):954-61 (1995).
50. Luger, S. M., J. Ratajczak, M. Z. Ratajczak, W. I. Kuczynski, R. S. DiPaola, W. Ngo, C. V. Clevenger, and A. M. Gewirtz: A functional analysis of protooncogene Vav's role in adult human hematopoiesis. Blood, 87(4):1326-34 (1996).
51. Murohashi, I., K. Endho, S. Nishida, S. Yoshida, I. Jinnai, M. Bessho, and K. Hirashima: Differential effects of TGF-beta 1 on normal and leukemic human hematopoietic cell proliferation. Exp. Hematol., 23(9):970-7 (1995).
52. Algar, E. M., T. Khromykh, S. I. Smith, D. M. Blackburn, G. J. Bryson, and P. J. Smith: A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene, 12(5):1005-14 (1996).
53. Anderegg, B., M. Horstmann, and H. Kabisch: Effects of anti-tal-1 oligodeoxynucleotides in T-ALL cell lines. Cancer Gene Ther., 4(2):84-90 (1997).
54. Prokocimer, M. and V. Rotter: Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood, 84(8):2391-411 (1994).
55. Bayever, E., K. M. Haines, P. L. Iversen, R. W. Ruddon, S. J. Pirruccello, C. P. Mountjoy, M. A. Arneson, and L. J. Smith: Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk. Lymphoma, 12(3- 4): 223-31 (1994).
56. Reed, J. C., T. Miyashita, S. Takayama, H. G. Wang, T. Sato, S. Krajewski, C. Aime-Sempe, S. Bodrug, S. Kitada, and M. Hanada: BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell Biochem., 60(1):23-32 (1996).
57. Melo, J. V.: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype [editorial; comment] [see comments]. Blood, 88(7):2375-84 (1996).
58. Szczylik, C., T. Skorski, N. C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, A. M. Gewirtz, and B. Calabretta: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science, 253(5019):562-5 (1991).
59. Skorski, T., C. Szczylik, L. Malaguarnera, and B. Calabretta: Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Histochem Cytobiol., 29(3):85-9 (1991).
60. Wu, A. G., S. S. Joshi, W. C. Chan, P. L. Iversen, J. D. Jackson, A. Kessinger, S. J. Pirruccello, W. G. Sanger, J. G. Sharp, D. J. Verbik, et al.: Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents. Leuk. Lymphoma, 20(12):67-76 (1995).
61. de Fabritiis, P., S. Amadori, B. Calabretta, and F. Mandelli: Elimination of clonogenic Philadelphia- positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone Marrow Transplant, 12(3):261-5 (1993).
62. de Fabritiis, P., T. Skorski, M. S. De Propris, M. G. Paggi, M. Nieborowska-Skorska, A. Lisci, S. Buffolino, K. Campbell, T. Geiser, and B. Calabretta: Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells. Leukemia, 11(6):811-9 (1997).
63. Chasty, R., A. Whetton, and G. Lucas: A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations. Leuk. Res., 20(5):391-5 (1996).
64. O'Brien, S. G., M. A. Kirkland, J. V. Melo, M. H. Rao, R. J. Davidson, C. McDonald, and J. M. Goldman: Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia, 8(12):2156-62 (1994).
65. Kirkland, M. A., S. G. O'Brien, C. McDonald, R. J. Davidson, N. C. Cross, and J. M. Goldman: BCR-ABL antisense purging in chronic myeloid leukaemia [letter; comment]. Lancet, 342(8871):614 (1993).
66. Maekawa, T., S. Kimura, K. Hirakawa, A. Murakami, G. Zon, and T. Abe: Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL antisense oligodeoxynucleoside phosphorothioates. Int. J. Cancer, 62(1):63-9 (1995).
67. Smetsers, T. F., L. T. van de Locht, A. H. Pennings, H. M. Wessels, T. M. de Witte, and E. J. Mensink: Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia, 9(1):118-30 (1995).
68. Vaerman, J. L., C. Lammineur, P. Moureau, P. Lewalle, F. Deldime, M. Blumenfeld, and P. Martial: BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood, 86(10):3891-6 (1995).
69. Mahon, F. X., J. Ripoche, V. Pigeonnier, B. Jazwiec, A. Pigneux, J. F. Moreau, and J. Reiffers: Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp. Hematol., 23(14):1606-11 (1995).
70. Leopold, L. H., S. K. Shore, and E. P. Reddy: Multiunit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. Leuk. Lymphoma, 22(56):365-73 (1996).
71. Lange, W., M. Daskalakis, J. Finke, and G. Dolken: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett., 338(2):175-8 (1994).
72. Pachuk, C. J., K. Yoon, K. Moelling, and L. R. Coney: Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to noncontiguous sequences. Nucleic Acids Res., 22(3):301-7 (1994).
73. Kronenwett, R., R. Haas, and G. Sczakiel: Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J. Mol. Biol., 259(4):632-44 (1996).
74. Rittner, K., C. Burmester, and G. Sczakiel: In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucleic Acids Res.,21(6):1381-1 (1993).
75. Ratajczak, M. Z., J. A. Kant, S. M. Luger, N. Hijiya, J. Zhang, G. Zon, and A. M. Gewirtz: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U.S.A., 89(24):11823-7 (1992).
76. Skorski, T., M. Nieborowska-Skorska, N. C. Nicolaides, C. Szczylik, P. Iversen, R. V. Iozzo, G. Zon, and B. Calabretta: Suppression of Philadelphial leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U.S.A., 91(10):4504-8 (1994).
77. Sawyers, C. L., W. Callahan, and O. N. Witte: Dominant negative MYC blocks transformation by ABL oncogenes. Cell, 70(6):901-10 (1992).
78. Sawyers, C. L.: The role of myc in transformation by BCR-ABL. Leuk. Lymphoma, 11(Suppl. 1):45-6 (1993).
79. Skorski, T., M. Nieborowska-Skorska, K. Campbell, R. V. Iozzo, G. Zon, Z. Darzynkiewicz, and B. Calabretta: Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med., 182(6):1645-53 (1995).
80. Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, G. Zon, R. V. Iozzo, and B. Calabretta: Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood, 88(3):1005-12 (1996).
81. Skorski, T., M. Nieborowska-Skorska, C. Barletta, L. Malaguarnera, C. Szcyzlik, S. T. Chen, B. Lange, and B. Calabretta: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest., 92(1):194-202 (1993).
82. Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, D. Perrotti, G. Hoser, J. Kawiak, M. Majewski, L. Christensen, R. V. Iozzo, and B. Calabretta: Treatment of Philadelphia leukemia in severe combined immuno-deficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides [see comments]. J. Natl. Cancer Inst., 89(2):124-33 (1997).
83. Bedi, A., B. A. Zehnbauer, M. I. Collector, J. P. Barber, M. S. Zicha, S. J. Sharkis, and R. J. Jones: BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood, 81(11):2898-902 (1993).
84. Bedi, A., B. A. Zehnbauer, J. P. Barber, S. J. Sharkis, and R. J. Jones: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood, 83(8):2038-44 (1994).
85. McGahon, A., R. Bissonnette, M. Schmitt, K. M. Cotter, D. R. Green, and T. G. Cotter: BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death [published erratum appears in Blood 1994 Jun 15; 83(12):3835]. Blood, 83(5):1179-87 (1994).
86. Kanei-Ishii, C., T. Nomura, K. Ogata, A. Sarai, T. Yasukawa, S. Tashiro, T. Takahashi, Y. Tanaka, and S. Ishii: Structure and function of the proteins encoded by the myb gene family. Curr. Top. Microbiol. Immunol., 211:89-98 (1996).
87. Nomura, N., Y. L. Zu, T. Maekawa, S. Tabata, T. Akiyama, and S. Ishii: Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1. J. Biol. Chem., 268(6):4259-66 (1993).
88. Biedenkapp, H., U. Borgmeyer, A. E. Sippel, and K. H. Klempnauer: Viral myb oncogene encodes a sequence-specific DNA-binding activity. Nature, 335(6193):835-7 (1988).
89. Siu, G., A. L. Wurster, J. S. Lipsick, and S. M. Hedrick: Expression of the CD4 gene requires a Myb transcription factor. Mol. Cell. Biol., 12(4):1592-604 (1992).
90. Melotti, P., D. H. Ku, and B. Calabretta: Regulation of the expression of the hematopoietic stem cell antigen CD34: role of c-myb. J. Exp. Med., 179(3):1023-8 (1994).
91. Gewirtz, A. M., G. Anfossi, D. Venturelli, S. Valpreda, R. Sims, and B. Calabretta: G1/S transition in normal human T-lymphocytes requires the nuclear protein encoded by c-myb. Science, 245(4914):180-3, (1989).
92. Caracciolo, D., D. Venturelli, M. Valtieri, C. Peschle, A. M. Gewirtz, and B. Calabretta: Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J. Clin. Invest., 85(1):55-61 (1990).
93. Mucenski, M. L., K. McLain, A. B. Kier, S. H. Swerdlow, C. M. Schreiner, T. A. Miller, D. W. Pietryga, W. J. Scott, Jr., and S. S. Potter: A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell, 65(4):677-89 (1991).
94. Anfossi, G., A. M. Gewirtz, and B. Calabretta: An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Nail. Acad. Sci. U.S.A., 86(9):3379-83 (1989).
95. Melotti, P. and B. Calabretta: Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb. Blood, 87(6):2221-34 (1996).
96. Vandenbark, G. R., Y. Chen, E. Friday, K. Pavlik, B. Anthony, C. deCastro, and R. E. Kaufman: Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements. Cell Growth Differ., 7(10):1383-92 (1996).
97. Ratajczak, M., D. Perrotti, P. Melotti, M. Powzaniuk, B. Calabretta, K. Onodera, D. Kregenow, B. Machalinski, and A. Gewirtz: Myb and Ets proteins are candidate regulators of c-kit expression in human hematopoietic cells. Blood, in press.
98. Yu, H., B. Bauer, G. K. Lipke, R. L. Phillips, and G. Van Zant: Apoptosis and hematopiesis in murine fetal liver. Blood, 81(2):373-384 (1993).
99. Carson, W. E., S. Haldar, R. A. Baiocchi, C. M. Croce, and M. A. Caligiuri: The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc. Natl. Acad. Sci. U.S.A., 91(16):7553-7 (1994).
100. Bonnefoy-Berard, N., A. Munshi, I. Yron, S. Wu, T. L. Collins, M. Deckert, T. Shalom-Barak, L. Giampa, E. Herbert, J. Hernandez, N. Meller, C. Couture, and A. Altman: Vav: function and regulation in hematopoietic cell signaling. Stern Cells, 14(3):250-68 (1996).
101. Katzav, S.: Vav: a molecule for all haemopoiesis? Br. J. Haematol., 81(2):141-4 (1992).
102. Katzav, S., D. Martin-Zanca, and M. Barbacid: Vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. EMBO J., 8(8):2283-90 (1989).
103. Katzav, S., J. L. Cleveland, H. E. Heslop, and D. Pulido: Loss of the amino-terminal helix-loop-helix domain of the vav protooncogene activates its transforming potential. Mol. Cell. Biol., 11(4):1912-20 (1991).
104. Galland, F., S. Katzav, and D. Birnbaum: The products of the mcf-2 and vav protooncogenes and of the yeast gene cdc-24 share sequence similarities. Oncogene, 7(3):585-7 (1992).
105. Cen, H., A. G. Papageorge, R. Zippel, D. R. Lowy, and K. Zhang: Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: identification of a region related to Bcr, Vav, Dbl and CDC24. EMBO J., 11(11):4007-15 (1992).
106. Alai, M., A. L. Mui, R. L. Cutler, X. R. Bustelo, M. Barbacid, and G. Krystal: Steel factor stimulates the tyrosine phosphorylation of the protooncogene product, p95vav, in human hemopoietic cells. J. Biol. Chem., 267(25):18021-5 (1992).
107. Clevenger, C. V., W. Ngo, D. L. Sokol, S. M. Luger, and A. M. Gewirtz: Vav is necessary for prolactin-stimulated proliferation and is translocated into the nucleus of a T-cell line. J. Biol. Chem., 270(22):13246-53 (1995).
108. Marengere, L. E., C. Mirtsos, I. Kozieradzki, A. Veillette, T. W. Mak, and J. M. Penninger: Protooncoprotein Vav interacts with c-Cbl in activated thymocytes and peripheral T cells. J. Immunol., 159(1):70-6 (1997).
109. Coppola, J., S. Bryant, T. Koda, D. Conway, and M. Barbacid: Mechanism of activation of the vav protooncogene. Cell Growth Differ., 2(2):95-105 (1991).
110. Adams, J. M., H. Houston, J. Allen, T. Lints, and R. Harvey: The hematopoietically expressed vav protooncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene, 7(4):611-8, (1992).
111. Wulf, G. M., C. N. Adra, and B. Lim: Inhibition of hematopoietic development from embryonic stem cells by antisense vav RNA. EMBO J., 12(13):5065-74 (1993).
112. Zhang, R., F. Y. Tsai, and S. H. Orkin: Hematopoietic development of vav-/- mouse embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A., 91(26):12755-9 (1994).
113. Zmuidzinas, A., K. D. Fischer, S. A. Lira, L. Forrester, S. Bryant, A. Bernstein, and M. Barbacid: The vav protooncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J., 14(1):1-11 (1995).
114. Zhang, R., F. W. Alt, L. Davidson, S. H. Orkin, and W. Swat: Defective signaling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav protooncogene. Nature, 374(6521):470-3 (1995).
115. Gewirtz, A. M., S. Luger, D. Sokol, B. Gowdin, E. Stadtmauer, A. Reccio, and M. Z. Ratajczak: Oligodeoxynucleotide therapeutics for human myelogenous leukemia: interim results. Blood, 88 (Suppl. 1) (10):270a (1996).
116. de Fabritis, P., S. Amadori, M. C. Petti, M. Mancini, E. Montefusco, A. Picardi, T. Geiser, K. Campbell, B. Calabretta, and F. Mandelli: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia, 9(4):662-4 (1995).
117. Bayever, E., P. L. Iversen, M. R. Bishop, J. G. Sharp, H. K. Tewary, M. A. Arneson, S. J. Pirruccello, R. W. Ruddon, A. Kessinger, G. Zon, et al.: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res. Dev., 3(4):383-90 (1993).
118. Bishop, M. R., P. L. Iversen, E. Bayever, J. G. Sharp, T. C. Greiner, B. L. Copple, R. Ruddon, G. Zon, J. Spinolo, M. Arneson, J. O. Armitage, and A. Kessinger: Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol., 14(4):1320-6 (1996).
119. Cotter, F. E., P. Johnson, P. Hall, C. Pocock, N. al Mahdi, J. K. Cowell, and G. Morgan: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9(10):3049-55 (1994).
120. Webb, A., D. Cunningham, F. Cotter, P. A. Clarke, F. di Stefano, P. Ross, M. Corbo, and Z. Dziewanowska: BCL-2 antisense therapy in patients with non-Hodgkin Iymphoma. Lancet, 349(9059):1137-41, 1997.
121. Loke, S. L., C. A. Stein, X. H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J. S. Cohen, and L. M. Neckers: Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. U.S.A., 86(10):3474-8 (1989).
122. Beltinger, C., H. U. Saragovi, R. M. Smith, L. LeSauteur, N. Shah, L. DeDionisio, L. Christensen, A. Raible, L. Jarett, and A. M. Gewirtz: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest., 95(4):1814-23 (1995).
123. Stein, C. A., K. Mod, S. L. Loke, C. Subasinghe, K. Shinozuka, J. S. Cohen, and L. M. Neckers: Phosphorothioate and normal oligodeoxyribonucleotides with 5′-linked acridine: characterization and preliminary kinetics of cellular uptake. Gene, 72(12):333-41 (1988).
124. Geselowitz, D. A., and L. M. Neckers: Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker. Antisense Res. Dev., 2(1):17-25 (1992).
125. Spiller, D. G., and D. M. Tidd: Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev., 5(1):13-21 (1995).
126. Lewis, J. G., K. Y. Lin, A. Kothavale, W. M. Flanagan, M. D. Matteucci, R. B. DePrince, R. A. Mook, Jr., R. W. Hendren, and R. W. Wagner: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. U.S..A., 93(8):3176-81 (1996).
127. Bergan, R., F. Hakim, G. N. Schwartz, E. Kyle, R. Cepada, J. M. Szabo, D. Fowler, R. Gress, and L. Neckers: Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood, 88(2):731-41 (1996).
128. Baskerville, S. and A. D. Ellington: RNA structure. Describing the elephant. Curr. Biol, 5(2):120-3 (1995).
129. Milner, N., K. U. Mir, and E. M. Southern: Selecting effective antisense reagents on combinatorial oligonucleotide arrays [see comments]. Nat. Biotechnol., 15(6):537-41 (1997).
130. Wagner, R. W.: The state of the art in antisense research. Nat. Med., 1(11):1116-8 (1995).
131. Stein, C. A. and A. M. Krieg: Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides [editorial]. Antisense Res. Dev., 4(2):67-9 (1994).